SIGA 8-K
Siga Technologies Inc (SIGA)
8-K
2025-11-06
For: 2025-11-06
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 6, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission file number)
|
(I.R.S. employer identification no.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip code)
|
Registrant’s telephone number, including area code: (212 ) 672-9100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 6, 2025, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the
quarter ended September 30, 2025.
Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is
being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.
The full text of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) The following exhibits are included in this report:
|
Exhibit
No.
|
Description
|
|
|
Earning Press Release issued on November 6, 2025.
|
||
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
SIGA TECHNOLOGIES, INC.
|
||
|
By:
|
/s/ Daniel J. Luckshire
|
|
|
Name:
|
Daniel J. Luckshire
|
|
|
Title:
|
Chief Financial Officer
|
|
|
Date: November 6, 2025
|
||
Exhibit 99.1
 |
 |
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
Corporate Update Conference Call Today at 4:30 PM ET
NEW YORK, November 6, 2025 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a
commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025.
“We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine
months of 2025," stated Diem Nguyen, Chief Executive Officer. " As we look forward to the remainder of 2025 and prepare for 2026, we are focused on building upon our long track record as a successful partner with the U.S. Government and
international governments to secure new procurement contracts and orders that will serve as the foundation of our revenues for the years to come.”
Summary Financial Results
|
($ in millions, except
per share amounts)
|
Three Months
Ended September 30
|
Nine Months
Ended September 30
|
||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Product sales (1)
|
$
|
0.9
|
$
|
8.9
|
$
|
85.8
|
$
|
53.5
|
||||||||
|
Total revenues (2)
|
$
|
2.6
|
$
|
10.0
|
$
|
90.8
|
$
|
57.3
|
||||||||
|
Operating (loss) / income(3) (4)
|
$
|
(10.2
|
)
|
$
|
0.5
|
$
|
33.2
|
$
|
12.9
|
|||||||
|
(Loss) / income before income taxes(3)
|
$
|
(8.4
|
)
|
$
|
1.9
|
$
|
38.3
|
$
|
17.5
|
|||||||
|
Net (loss) / income
|
$
|
(6.4
|
)
|
$
|
1.3
|
$
|
28.7
|
$
|
13.5
|
|||||||
|
Diluted (loss) / income per share
|
$
|
(0.09
|
)
|
$
|
0.02
|
$
|
0.40
|
$
|
0.19
|
|||||||
|
(1)
|
Includes supportive services related to product sales.
|
|
(2)
|
Includes research and development revenues.
|
|
(3)
|
Operating (loss) / income excludes, and income (loss) before income taxes includes, other
income. Both line items exclude the impact of income taxes.
|
|
(4)
|
Differences in operating income margin between periods reflects different product mixes in those periods.
|
|
|
Year-to-Date Key Business and Operational Activity:
| • |
For the first nine months of the year, the Company generated $53 million
of oral TPOXX revenues and $26 million of IV TPOXX revenues in connection with deliveries to the U.S. Strategic National Stockpile, or SNS. Additionally, the Company delivered $6 million of oral
TPOXX to an international customer, representing a sale to this country in five out of the last six years.
|
| • |
In June 2025, the Company’s Biomedical Advanced Research and Development
Authority, or BARDA, 19C contract (with the U.S. Government) was modified to add $13 million of funding to the Company’s TPOXX pediatric development program. In combination with the $14 million of funding added in April 2025 to support
manufacturing activities, $27 million of development funding was added to the BARDA 19C contract during the second quarter.
|
| • |
In March 2025, the Company received a procurement order for $26 million of IV TPOXX from the U.S. Government under the 19C BARDA contract.
|
| • |
In January 2025, the Company announced that TPOXX received regulatory approval in Japan (as TEPOXX) for the treatment of smallpox, mpox, cowpox, as well as
complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. TEPOXX is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency (PDMA), in collaboration with the
Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses.
|
Capital Management Activity:
On April 8, 2025, a special cash dividend of $0.60 per share was declared. This dividend was paid on May 15, 2025 to shareholders of
record at the close of business on April 29, 2025.
Conference Call and Webcast
SIGA will host a conference call and webcast to provide a business update today, Thursday, November 6, 2025, at 4:30 P.M. ET.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A live webcast of the call
will also be available on the Company's website at www.siga.com in the Investor Relations section of the website, or by clicking here. Please log in approximately 5-10 minutes
prior to the scheduled start time.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using
Conference ID: 1141989. The archived webcast will be available in the Investor Relations section of the Company's website.
|
|
ABOUT SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health
focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those
that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our
flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia
complications. For more information about SIGA, visit www.siga.com.
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including
statements relating to SIGA’s future business development and plans. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future
operations. The words “may,” “continue,” “estimate,” “intend,” “plan,” “will,” “believe,” “project,” “expect,” “seek,” “anticipate,” “could,” “should,” “target,” “goal,” “potential” and similar expressions may identify forward-looking statements,
but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking
information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond
SIGA’s control, including, but not limited to, (i) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (ii) the risk that the BARDA Contract is modified or canceled at the
request or requirement of, or SIGA is not able to enter into new contracts to supply TPOXX® to, the U.S. Government, (iii) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to
successfully market TPOXX® internationally, (iv) the risk that potential products, including potential alternative uses or formulations of TPOXX® that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in
subsequent pre-clinical or clinical trials, (v) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing
organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vi) the risk that SIGA or its collaborators will not obtain or maintain appropriate or necessary
governmental approvals to market these or other potential products or uses, (vii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (viii) the risk that
any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (ix) the risk that regulatory requirements applicable to SIGA’s products may
result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking, obtaining or maintaining needed approvals to market these products, (x) the risk that the volatile and competitive nature of the
biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xi) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products
adversely, (xii) the effect of federal, state, and foreign regulation, including drug regulation, on SIGA’s businesses, (xiii) the impacts of significant recent shifts in trade policies, including the imposition of tariffs, retaliatory tariff
measures, and subsequent modifications or suspensions thereof, and market reactions to such policies and resulting trade disputes, (xiv) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s
research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xv) risks associated with
the U.S. Government shutdown, actions or uncertainties surrounding the debt ceiling, or the changes in the U.S. administration, and (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic
conditions or infectious diseases, are ineffective and may adversely affect SIGA’s business, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2024 and
SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current
only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect
the occurrence of unanticipated events. The information contained on any website referenced in this Form 10-Q is not incorporated by reference into this filing.
Contacts:
|
Investors
|
Media
|
|
Suzanne Harnett
|
Holly Stevens, CG Life
|
|
|
SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
As of
|
|
September
30, 2025
|
December 31,
2024
|
||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$
|
171,955,584
|
$
|
155,400,262
|
||||
|
Accounts receivable
|
2,490,234
|
21,166,129
|
||||||
|
Inventory
|
48,006,005
|
49,563,880
|
||||||
|
Prepaid expenses and other current assets
|
5,293,648
|
4,914,613
|
||||||
|
Total current assets
|
227,745,471
|
231,044,884
|
||||||
|
|
||||||||
|
Property, plant and equipment, net
|
1,196,803
|
1,298,423
|
||||||
|
Deferred tax asset, net
|
1,560,453
|
10,854,702
|
||||||
|
Goodwill
|
898,334
|
898,334
|
||||||
|
Other assets
|
202,015
|
240,683
|
||||||
|
Total assets
|
$
|
231,603,076
|
$
|
244,337,026
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$
|
5,032,898
|
$
|
1,340,337
|
||||
|
Accrued expenses and other current liabilities
|
9,472,862
|
5,640,110
|
||||||
|
Deferred IV TPOXX® revenue
|
10,240,000
|
10,330,800
|
||||||
|
Income tax payable
|
96,561
|
8,020,366
|
||||||
|
Total current liabilities
|
24,842,321
|
25,331,613
|
||||||
|
|
||||||||
|
Other liabilities
|
3,281,879
|
3,200,650
|
||||||
|
Total liabilities
|
28,124,200
|
28,532,263
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity
|
||||||||
|
Common stock ($.0001 par value, 600,000,000 shares authorized, 71,611,302 and 71,404,669, issued and outstanding at September 30, 2025 and December 31, 2024,
respectively)
|
7,161
|
7,140
|
||||||
|
Additional paid-in capital
|
241,112,674
|
238,635,635
|
||||||
|
Accumulated deficit
|
(37,640,959
|
)
|
(22,838,012
|
)
|
||||
|
Total stockholders’ equity
|
203,478,876
|
215,804,763
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
231,603,076
|
$
|
244,337,026
|
||||
|
|
SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(UNAUDITED)
|
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30, |
||||||||||||||
|
|
2025
|
2024
|
2025
|
2024
|
||||||||||||
|
Revenues
|
||||||||||||||||
|
Product sales and supportive services
|
$
|
889,748
|
$
|
8,942,875
|
$
|
85,835,855
|
$
|
53,496,869
|
||||||||
|
Research and development
|
1,730,252
|
1,066,906
|
4,944,963
|
3,753,658
|
||||||||||||
|
Total revenues
|
2,620,000
|
10,009,781
|
90,780,818
|
57,250,527
|
||||||||||||
|
|
||||||||||||||||
|
Operating expenses
|
||||||||||||||||
|
Cost of sales and supportive services
|
1,002,083
|
1,620,510
|
26,714,283
|
17,157,508
|
||||||||||||
|
Selling, general and administrative
|
4,786,511
|
4,822,591
|
15,949,749
|
18,228,786
|
||||||||||||
|
Research and development
|
7,053,985
|
3,024,593
|
14,914,895
|
8,966,905
|
||||||||||||
|
Total operating expenses
|
12,842,579
|
9,467,694
|
57,578,927
|
44,353,199
|
||||||||||||
|
Operating (loss)/income
|
(10,222,579
|
)
|
542,087
|
33,201,891
|
12,897,328
|
|||||||||||
|
Other income, net
|
1,866,693
|
1,330,505
|
5,143,981
|
4,590,935
|
||||||||||||
|
(Loss)/Income before income taxes
|
(8,355,886
|
)
|
1,872,592
|
38,345,872
|
17,488,263
|
|||||||||||
|
Benefit/(Provision) for income taxes
|
1,990,067
|
(528,647
|
)
|
(9,636,811
|
)
|
(4,034,362
|
)
|
|||||||||
|
Net and comprehensive (loss)/income
|
$
|
(6,365,819
|
)
|
$
|
1,343,945
|
$
|
28,709,061
|
$
|
13,453,901
|
|||||||
|
Basic (loss)/income per share
|
$
|
(0.09
|
)
|
$
|
0.02
|
$
|
0.40
|
$
|
0.19
|
|||||||
|
Diluted (loss)/income per share
|
$
|
(0.09
|
)
|
$
|
0.02
|
$
|
0.40
|
$
|
0.19
|
|||||||
|
Weighted average shares outstanding: basic
|
71,604,956
|
71,368,585
|
71,499,984
|
71,191,019
|
||||||||||||
|
Weighted average shares outstanding: diluted
|
71,604,956
|
71,766,503
|
71,801,188
|
71,853,341
|
||||||||||||